The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
Open accessAbstract
Background Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overall survival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in a compassionate-use program.Patients and methods In this prospective study, patients were treated between June 2010 and September 2011. Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy, and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kg every 3 weeks.Results Seventy-three patients were included. Median OS was 9.1 months (95% CI 6.4-11.3) from the start of ipilimumab. Immune-related adverse events were observed in 45 patients (62%), including 19 grade 3-4 events (26%). No drug-related death occurred. A lymphocyte count >1000/mm(3) at the start of the second course and an increase in the eosinophil count >100/mm(3) between the first and second infusions were correlated with an improved OS.Conclusion Ipilimumab toxic effect is manageable in real life. Biological data such as lymphocyte and eosinophil counts at the time of the second ipilimumab infusion appear to be early markers associated with better OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEstimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,032
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova‐Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,323
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Management of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 869
Flagged first, then by citations
Research works printed but not linked: 1
- Squibb, 2011, YERVOY™ (ipilimumab) Immune-mediated adverse reaction management guide
Cited by
Sorted by citations
Items 201–300 of 318
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab
Heine, A., Kristiansen, G., Schild, H. H., & Brossart, P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw243 · Cited by 18
Umemura, H., Yamasaki, O., Kaji, T., Otsuka, M., Asagoe, K., Takata, M., & Iwatsuki, K. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13651 · Cited by 18
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab
Brüggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krähenbühl, L., Kähler, K. C., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2450-2 · Cited by 19
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
Tunger, A., Kießler, M., Wehner, R., Temme, A., Meier, F. E., Bachmann, M. P., & Schmitz, M. (2018) · Biomedicines · doi:10.3390/biomedicines6010026 · Cited by 18
Assi, H., Asch, A. S., Machiorlatti, M. G., Vesely, S. K., & Ibrahimi, S. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0021 · Cited by 19
Hung, Y., Shao, Y., Lee, J., Hsu, C., Hsu, C., Yang, M., & Chao, Y. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000477 · Cited by 18
Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
Occhipinti, M. A., Falcone, R., Onesti, C. E., & Marchetti, P. (2018) · Drug Safety - Case Reports · doi:10.1007/s40800-018-0078-z · Cited by 17
Zhu, Z., Zhuang, L., Zhang, C., Ning, Z., Wang, D., Sheng, J., Hua, Y.-Q., Xie, J., Xu, L., & Meng, Z. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-1760 · Cited by 16
Wendlinger, S., Wohlfarth, J., Kreft, S., Siedel, C., Kilian, T., Dischinger, U., Heppt, M. V., Wistuba‐Hamprecht, K., Meier, F. E., Goebeler, M., et al. (2022) · Cancers · doi:10.3390/cancers14092294 · Cited by 19
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Albarrán-Artahona, V., Laguna, J. C., Gorría, T., Torres-Jiménez, J., Pascal, M., & Mezquita, L. (2022) · Diagnostics · doi:10.3390/diagnostics12092091 · Cited by 17
Xu, Jin, C., Zhang, X., Zhao, K., Xu, J., & Zhao, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s96762 · Cited by 15
High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
Quek, C. Y. J., Bai, X., Long, G. V., Scolyer, R. A., & Wilmott, J. S. (2021) · Genes · doi:10.3390/genes12101629 · Cited by 16
Wagner, N. B., Luttermann, F., Gassenmaier, M., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13248 · Cited by 15
Targeting the immune system to treat lung cancer: rationale and clinical experience
Guibert, N. M., Delaunay, M., & Mazières, J. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815578349 · Cited by 14
Veal, G. J., Amankwatia, E. B., Paludetto, M., Möcklinghoff, T., THOMSON, F. J., André, N., Ciccolini, J., & Chatelut, É. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000606 · Cited by 14
Biological basis of extensive pleiotropy between blood traits and cancer risk
Pardo-Cea, M. Á., Farré, X., Esteve, A., Palade, J., Espín, R., Mateo, F., Alsop, E. B., Alorda, M., Blay, N., Baiges, A., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01294-8 · Cited by 12
Omero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., & Santarpía, M. (2025) · Biomolecules · doi:10.3390/biom15040491 · Cited by 13
Toshida, K., Itoh, S., Yoshiya, S., Nagao, Y., Tomino, T., Izumi, T., Iseda, N., Toshima, T., Ninomiya, M., & Yoshizumi, T. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16441 · Cited by 12
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
Kim, H. Y., Upadhyay, P. J., Fahmy, A., Liu, X., Duong, J. K., & Boddy, A. V. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00753-5 · Cited by 13
Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer
Fujiwara, R., Inamura, K., Yuasa, T., Numao, N., Yamamoto, S., Masuda, H., Kawauchi, A., Takeuchi, K., & Yonese, J. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01542-7 · Cited by 12
Voutsadakis, I. A. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.03 · Cited by 13
Sumiyoshi, I., Okabe, T., Togo, S., Takagi, H., Motomura, H., Ochi, Y., Shimada, N., Haraguchi, M., Shibayama, R., Fujimoto, Y., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02761-1 · Cited by 12
Ma, J., Sun, G., Zhu, P., Liu, S., Ou, M., Chen, Z., Zou, C., Chan, F. L., Dai, Y., & Sui, W. (2019) · Oncology Letters · doi:10.3892/ol.2019.10015 · Cited by 11
Overview of Basic Immunology and Clinical Application
Stephen, B., & Hajjar, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_1 · Cited by 11
Kartolo, A., Holstead, R. G., Hopman, W. M., & Baetz, T. D. (2020) · Immunotherapy · doi:10.2217/imt-2020-0265 · Cited by 11
Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
Rogers, C. B. B., Zawislak, M. C., & Victoria Wong, P.-C. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.4.4 · Cited by 11
Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer
Grundy, M., Coussios, C. C., & Carlisle, R. C. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1167036 · Cited by 10
Ma, Y., Shang, K., Wu, S., Wang, J., & Cao, B. (2022) · Nutrition and Cancer · doi:10.1080/01635581.2022.2032764 · Cited by 10
Ürün, Y., Yaşar, A., Turna, H., Esin, E., Sedef, A. M., Alkan, A., Öksüzoğlu, B. Ç., Özdemir, N., Sendur, M. N., Sezer, A., et al. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218805539 · Cited by 10
Wissam, Y., Belcaid, L., Wittoek, R., Smith, V. M., Vanhaecke, A., Schepper, S. D., Jans, L. B. O., de Roodenbeke, D. '. K., Gombos, A., & Aspeslagh, S. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_8_19 · Cited by 9
Kurzhals, J. K., Klee, G., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810723 · Cited by 9
Eosinophils in metastatic melanoma
Proffer, S. L., Guo, R., Demer, A. M., & Peters, M. S. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.08.001 · Cited by 9
Moreira, A., Erdmann, M., Uslu, U., Vass, V., Schuler, G., & Schuler‐Thurner, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030210 · Cited by 9
Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices
Pagès, F., Granier, C., Kirilovsky, A., Sissy, C. E., & Tartour, É. (2016) · Bulletin du Cancer · doi:10.1016/s0007-4551(16)30373-3 · Cited by 8
Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer
Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V. P., Gul, A. R. Z., Shahab Uddin, M. S., Homsi, M. U. A., & Dermime, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96494 · Cited by 8
Proteomics: An Indispensable Tool for Novel Biomarker Identification in Melanoma
Mittal, P., & Jain, M. (2016) · Journal of Data Mining in Genomics & Proteomics · doi:10.4172/2153-0602.1000204 · Cited by 7
Singh, N., Lubana, S. S., Constantinou, G., & Leaf, A. N. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/7492634 · Cited by 8
L’immunothérapie dans le mélanome
Routier, É., Robert, C., & Mateus, C. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.2054 · Cited by 9
Self-citationCASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL
Russi, A., Chiarion‐Sileni, V., Damuzzo, V., Sarra, F. D., Pigozzo, J., & Palozzo, A. C. (2017) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462317000332 · Cited by 7
Badami, S., Upadhaya, S., Velagapudi, R. K., Mikkilineni, P., Kunwor, R., Hadidi, S. A., & Bachuwa, G. I. (2018) · Journal of Oncology · doi:10.1155/2018/6279871 · Cited by 7
Overview of Basic Immunology and Translational Relevance for Clinical Investigators
Stephen, B., & Hajjar, J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_1 · Cited by 7
A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma
Tsuji, A., Hiramatsu, K., Namikawa, S., Yamamoto, A., Midori, Y., Murata, Y., Tanaka, T., Nosaka, T., Naito, T., Takahashi, K., et al. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01680-y · Cited by 6
Kageyama, S., Yoshida, T., KOBAYASHI, K. P., Wada, A., Nagasawa, M., Kubota, S., Kusaba, T., Jo, F., Nakagawa, S., Johnin, K., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13635 · Cited by 6
Brand, C. L., Hunger, R. E., & Jafari, S. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1366081 · Cited by 6
Russi, A., Damuzzo, V., Chiumente, M., Pigozzo, J., Cesca, M., Chiarion‐Sileni, V., & Palozzo, A. C. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1311444 · Cited by 6
Prospect for Immune Checkpoint Blockade: Dynamic and Comprehensive Monitorings Pave the Way
Wang, W., Liu, J., He, Y., & McLeod, H. L. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0053 · Cited by 6
Rapoport, B. L., Vorobiof, D., Dreosti, L., Nosworthy, A. L., McAdam, G. L., Jordaan, J. P., Miller-Jansön, H., de Necker, M., de Beer, J. C., & Duvenhage, H. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.006544 · Cited by 5
Ugurel, S., Kiecker, F., Fröhling, S., Wetter, A., Bánkfalvi, Á., Sucker, A., Zimmer, L., Livingstone, E., Roesch, A., Becker, J. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.020 · Cited by 5
Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer
Samancı, N. Ş., Çıkman, D. İ., Oruç, K., Bedir, Ş., Çelik, E., Değerli, E., Derin, S., Demirelli, F. H., & Özgüroğlu, M. (2020) · Tumori Journal · doi:10.1177/0300891620953468 · Cited by 5
Yoshimura, A., Nagahara, A., Ishizuya, Y., Yamamoto, Y., Hatano, K., Kawashima, A., Nakai, Y., Nakayama, M., Nishimura, K., Nonomura, N., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01370-8 · Cited by 5
Martínez-Vila, C., González‐Navarro, E. A., Teixidó, C., Martin, R., Aya, F., Juan, M., & Arance, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179506 · Cited by 5
Overview of Basic Immunology for Clinical Investigators
Stephen, B., & Hajjar, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_1 · Cited by 5
Singh, P., SOUZA, P. D., Scott, K. F., Hall, B. M., Verma, N. D., Becker, T. M., Toh, J. W. T., Sajinovic, M., & Spring, K. J. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0032-9 · Cited by 5
Lyu, L., Bian, S., Guan, K., & Zhao, B. (2025) · International Journal of Cancer · doi:10.1002/ijc.35398 · Cited by 4
Biomarkers for immune checkpoint inhibitors in solid tumors
Kapoor, V., & Kelly, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02942-4 · Cited by 4
Reddy, Y. K., Fischer, I. S., Kolodney, J. A., & Willard, M. (2023) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001075 · Cited by 4
Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment
Mima, Y., Ohtsuka, T., Ebato, I., Nakata, Y., Tsujita, A., Nakazato, Y., & Norimatsu, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12081886 · Cited by 5
Diamantopoulos, P. T., Gkoufa, A., Anastasopoulou, A. N., Kouzis, P., Lyrarakis, G., Kyriakakis, G., & Gogas, H. J. (2025) · Cancer Medicine · doi:10.1002/cam4.70679 · Cited by 4
Mélanome — Thérapeutique par les médications : anticorps anti-CTLA-4 et anti-PD1
Robert, C., & Mateus, C. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31343-3 · Cited by 4
Self-citationOrgan-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
Zheng, X., & Wei, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628243 · Cited by 4
Osawa, H., Shiozawa, T., Okauchi, S., Sasatani, Y., Ohara, G., Sato, S., Miyazaki, K., Kodama, T., Kagohashi, K., Satoh, H., et al. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10065 · Cited by 4
Eosinophil plays a crucial role in intestinal mucositis induced by antineoplastic chemotherapy
Arifa, R. D. D. N., de Brito, C. B., de Paula, T. P., Lima, R. L., Garcia, Z. M., Vieira, P. C., Boas, F. D. A. S. V., Queiroz‐Junior, C. M., da Silva, J. M., Silva, T. A., et al. (2021) · Immunology · doi:10.1111/imm.13442 · Cited by 4
The emerging development of tumor mutational burden in patients with NSCLC
Zhang, Y., Wang, L., Li, R., & Liu, B. (2020) · Future Oncology · doi:10.2217/fon-2019-0650 · Cited by 4
Proteomics as a Potential Tool for Biomarker Discovery
Dalal, V., Dhankhar, P., & Biswas, S. (2022) · Springer eBooks · doi:10.1007/978-981-19-1008-1_8 · Cited by 3
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies
Danielli, R., Cutaia, O., Fazio, C., Bertocci, E., Fonsatti, E., Maio, M., & Calabrò, L. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3338-9_13 · Cited by 3
Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns
Frelau, A., Pracht, M., Sourd, S. L., Lespagnol, A., Corre, R., Menard, C., Tarte, K., Mosser, J., & Edeline, J. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(18)30393-x · Cited by 6
Therapeutic Drug Monitoring as a Tool for Therapy Optimization
Pavithran, K., & Babu, M. (2022) · Drug Metabolism and Bioanalysis Letters · doi:10.2174/1872312815666220405122021 · Cited by 3
Ladouceur, A., Ezdoglian, A. A., Sparks, J. A., Hudson, M., Jamal, S., Clifford, A. H., Roberts, J., & Ye, C. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.01.003 · Cited by 4
Kim, J., Kim, H., Lim, J. H., & Nam, W. (2014) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2014.06.006 · Cited by 3
Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting
Eggermont, A. M. M., & Robert, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_34 · Cited by 3
Self-citationCarnio, S., Mariniello, A., Pizzutilo, P., Numico, G., Borra, G., Lunghi, A., Parra, H. J. S., Buosi, R., Vavalà, T., Stura, I., et al. (2020) · Journal of Molecular Pathology · doi:10.3390/jmp1010004 · Cited by 3
Gambichler, T., Overbeck, J., Rached, N. A., Susok, L., & Weyer-Fahlbusch, S. S. (2025) · Journal of Skin Cancer · doi:10.1155/jskc/2561307 · Cited by 2
Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies
Gilon, M., Boulet, D., Bours, V., Jérusalem, G., Josse, C., & Gennigens, C. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03688-5 · Cited by 3
Zong, Y., Yang, M., Zhang, J., Zou, Y., Ye, Z., Deng, J., Gu, W., Ohno‐Matsui, K., & Kamoi, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135944 · Cited by 2
Kuo, Y. (2024) · American Journal of Cancer Research · doi:10.62347/sspi9013 · Cited by 2
Biomarkers in Melanoma: where are we now?
Johnson, D. B., & Sullivan, R. J. (2014) · Melanoma Management · doi:10.2217/mmt.14.19 · Cited by 2
The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab
Puri, S., & Markowitz, J. (2017) · Annals of Research Hospitals · doi:10.21037/arh.2017.04.24 · Cited by 2
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem, S., Fässler, M., Ali, O. H., Siano, M., Niederer, R., Berner, F., Roux, G.-A., Ackermann, C. J., Schmid, S., Güsewell, S., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s179767 · Cited by 2
Stephen, B., & Hajjar, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_1 · Cited by 2
Sex differences in innate immune cell responses: Impact on cancer immunity and response to therapy
Ramin, S., & Medler, T. R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864861 · Cited by 1
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Ascierto, P. A., Munn, D. H., Palucka, A. K., & Sondel, P. M. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-15 · Cited by 1
Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado
Gago, M. C. P., Gadea, O. S. S., & de la Cruz‐Merino, L. (2017) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2017.01.016 · Cited by 1
Blagosklonny, M. V., & Gudkov, A. V. (2010) · Oncotarget · doi:10.18632/oncotarget.24001 · Cited by 1
Ray, A., Pathak, S., Ghorai, S., Bhushan, B., Banerjee, S., & Ghosh, S. (2023) · Indian Journal of Public Health Research & Development · doi:10.37506/ijphrd.v14i3.19351 · Cited by 1
A Rare Presentation of Malignant Melanoma of the Face: A Case Report
Palatkar, A., Jain, Y. V., Babu, M. S., Shinde, V., & Ingale, M. H. (2024) · Cureus · doi:10.7759/cureus.64797 · Cited by 1
Predictive Biomarkers of Melanoma
Hanly, A. M., Gibson, F. T., & Alani, R. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_16 · Cited by 1
Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure
Eggermont, A. M. M., Schadendorf, D., & Robert, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_17
Self-citationAdvances in the Immunobiological Therapies for Advanced Melanoma
Gago, M. C. P., Gadea, O. S. S., & de la Cruz‐Merino, L. (2017) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2017.01.005
Predictors of Response to Immune Checkpoint Blockade
Andrews, M. C., & Wargo, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_31
WITHDRAWN: Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns
Frelau, A., Pracht, M., Sourd, S. L., Lespagnol, A., Corre, R., Menard, C., Tarte, K., Mosser, J., & Edeline, J. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.10.031
Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics
Kulkarni, P. D., Mehta, P., Shriyan, B., Gawit, K., Gota, V., & Ghante, M. R. (2020) · Springer eBooks · doi:10.1007/978-981-15-9038-2_9
Pinilla, P. A., Maya, R. E. B., & Pedraza, R. S. (2019) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.4
Castello, A., & Lopci, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-68858-5_8
Staring a project-management organization - a utility perspective
Santoro, P., & Nadeau, L. (1988) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Improving immunotherapy responses in gastrointestinal cancers
Chalabi, M. (2022) · doi:10.33540/904
Proverbs-Singh, T. A., Wolchok, J. D., & Snyder, A. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch4
(2015) · Reactions Weekly · doi:10.1007/s40278-015-3636-5
Faculty Opinions recommendation of Nivolumab plus ipilimumab in advanced melanoma.
Pawelec, G. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718016388.793481265
Novello, S., Migliaretti, G., Galetta, D., Tabbò, F., Montrone, M., Alemanni, A., Genestroni, S., Stura, I., Vavalà, T., Buosi, R., et al. (2021) · Advanced Biomedicine · doi:10.54730/abm.2021.030503
Metadata
- Authors
- Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C.
- Affiliations
- Institut Gustave Roussy (FR)
- Université Paris-Sud (FR)
- Inserm (FR)
- Corresponding author
- Delyon, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 24
- Issue
- 6
- Pages
- 1697-1703
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2107863654
- Semantic Scholar
- 227acc6dc2205788c75d438e03d62ffe4cfd3073
- Cited by
- 318
- References
- 23
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 10 · 2023: 11 · 2022: 21 · 2021: 28 · 2020: 36 · 2019: 31 · 2018: 31 · 2017: 43 · 2016: 36 · 2015: 32 · 2014: 13 · 2013: 9
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, immune checkpoint inhibitors, overall survival, lymphocyte count, eosinophil count, immune-related adverse events, prognostic factors, compassionate use program
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Eosinophils, Female, Humans, Lymphocytes, Male, Melanoma, Middle Aged, Prospective Studies, Skin Neoplasms, Time Factors, Survival Rate, Treatment Outcome, Lymphocyte Count, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
